Telangana: Five hospitals get notices for violating norms

The notices issued to the five hospitals of the district headquarters asked the hospital to explain within three days on why action should not be taken against them for flouting norms.

Published On 2022-10-04 04:15 GMT   |   Update On 2022-10-04 04:15 GMT

Mancherial: Around five hospitals in Mancherial were issued notices by the officials of the medical and health department for violating various ruled by displaying name boards. According to the statement issued by the District Medical and Health Officer Dr. Subbarayudu, the action was taken after the department conducted its fortnight-long inspections which began on 23rd September to...

Login or Register to read the full article

Mancherial: Around five hospitals in Mancherial were issued notices by the officials of the medical and health department for violating various ruled by displaying name boards. 

According to the statement issued by the District Medical and Health Officer Dr. Subbarayudu, the action was taken after the department conducted its fortnight-long inspections which began on 23rd September to prevent wrongdoings and violations of the rules. 

Also Read:Tamil Nadu: Upgradation of Government Headquarters Hospital to be completed by December

Five special teams were formed for the inspection, and they have inspected 71 hospitals so far, reports Telangana Today. 

The notices issued to the five hospitals of the district headquarters asked the hospital to explain within three days on why action should not be taken against them for flouting norms. It has been reported that the hospitals were found displaying name boards and were providing services in violation of the rules. 

Medical Dialogues team had earlier reported about a similar incident where an announcement had been made by the Pharma major, Lupin stating that the Company had received a warning letter from the US Food and Drug Administration (USFDA) for the Company's Tarapur, Maharashtra (India) facility. The USFDA inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022. In their BSE filing, the ccompany sgtated, "The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility."  It also noted that they are committed to addressing the concerns raised by the U.S. FDA and would work with the U.S. FDA to resolve these issues at the earliest. They observed, "We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities." 

Also Read:USFDA inspection: Lupin gets warning letter for Tarapur facility

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News